INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on December 5, 2022, covering events occurring between November 29, 2022, and December 2, 2022. The company is incorporated in Nevada and its common stock is registered on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing details the creation of a direct financial obligation through the issuance of demand promissory notes totaling $150,000. The filing does not provide data on revenue, profit, cash flow, margins, or overall liquidity positions outside of this specific transaction.
- Total Proceeds: $150,000
- Lenders: Chief Executive Officer Steven Shum ($75,000 total) and an entity controlled by Chief Financial Officer Andrea Goren ($75,000).
- Interest Terms: Interest-free if paid prior to January 31, 2023. Outstanding amounts after this date accrue 10% annual interest from the issuance date.
- Repayment Terms: At maturity, the Company must pay outstanding principal, a 10% financing fee, and any accrued interest.
- Callability: Notes are callable with 10 days' prior written notice, exercisable starting 30 days from issuance.
Material Changes
The primary material change reported is the increase in short-term debt obligations due to the issuance of the promissory notes described above. No other material changes to financial condition or operations are disclosed in this specific filing.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the financing. The filing notes that the summary of the notes is qualified by reference to the full text of the exhibits. There are no specific forward-looking guidance statements or new risk factors disclosed in this report beyond the obligation to repay the debt with a financing fee.
Investor Verification Checklist
- Verify the total outstanding debt load of the company by reviewing the most recent 10-K or 10-Q filings to contextualize the $150,000 obligation.
- Confirm the company's cash position to assess its ability to repay the notes before the January 31, 2023, interest-free deadline.
- Review the full text of Exhibits 4.1, 4.2, and 4.3 for any additional covenants or default provisions not summarized in the 8-K.
- Monitor for any subsequent filings regarding the repayment or extension of these notes.